All Pathways
Family MedicineDiagnostic

Anxiety Disorders Screening & Initial Management (GAD-7)

Anxiety Disorders Screening & Initial Management (GAD-7): Anxiety Screening → GAD-2 Initial Screen → GAD-2 Negative (<3).

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Anxiety Screening

    Consider screening patients with unexplained somatic symptoms or worry

    1. Action

      GAD-2 Initial Screen

      2-question screening tool

      • Over last 2 weeks, how often have you:
      • 1. Feeling nervous, anxious, or on edge?
      • 2. Not being able to stop or control worrying?
      • Score 0-3 for each (Not at all=0 to Nearly every day=3)
      • Positive screen: Total ≥3
      1. Outcome

        GAD-2 Negative (<3)

        Unlikely GAD, consider other causes if symptomatic

      2. Action

        Complete GAD-7

        Full 7-item anxiety severity assessment

        • Add 5 more questions covering:
        • Trouble relaxing, restlessness
        • Irritability, fear of something awful
        • Total score 0-21
        • Also ask about panic attacks, specific fears
        1. Decision

          Rule Out Medical Causes

          Consider organic etiologies

          • Hyperthyroidism (TSH)
          • Caffeine/stimulant use
          • Medication side effects
          • Cardiac arrhythmias
          • Pheochromocytoma (rare)
          1. Decision

            GAD-7 Severity Score

            Determine anxiety severity

            • 0-4: Minimal anxiety
            • 5-9: Mild anxiety
            • 10-14: Moderate anxiety
            • 15-21: Severe anxiety
            1. Action

              Minimal/Mild (0-9)

              Watchful waiting with self-help

              • Patient education about anxiety
              • Self-help resources (apps, workbooks)
              • Lifestyle: exercise, sleep, caffeine reduction
              • Breathing exercises, relaxation techniques
              • Reassess in 2-4 weeks if persistent
              1. Action

                Moderate (10-14)

                Initiate treatment

                • Offer choice: SSRI/SNRI OR CBT
                • First-line: Sertraline, escitalopram, or duloxetine
                • CBT (8-12 sessions) equally effective
                • Avoid benzodiazepines as first-line
                • Follow up in 2-4 weeks
                1. Decision

                  Differentiate Anxiety Disorder Type

                  Guide specific treatment

                  • GAD: Persistent worry about multiple domains
                  • Panic Disorder: Recurrent unexpected panic attacks
                  • Social Anxiety: Fear of social scrutiny
                  • Specific Phobia: Fear of specific object/situation
                  • PTSD: Following traumatic event
                  1. Action

                    SSRI/SNRI Selection

                    First-line pharmacotherapy

                    • Sertraline: Start 25-50mg, target 50-200mg
                    • Escitalopram: Start 5-10mg, target 10-20mg
                    • Duloxetine (SNRI): Start 30mg, target 60-120mg
                    • Buspirone: Alternative, 5mg TID to 30mg BID
                    • Allow 4-6 weeks for full effect
                    1. Action

                      Treatment Follow-Up

                      Monitor response

                      • Repeat GAD-7 at each visit
                      • Response: ≥50% reduction in GAD-7
                      • Remission: GAD-7 <5
                      • If no response 6-8 weeks: switch medication class
                      • Consider augmentation or combination therapy
                      1. Outcome

                        Remission Achieved

                        Continue 6-12 months, then gradual taper

                      2. Warning

                        Psychiatry Referral

                        Refractory or complex cases

                        • Inadequate response to 2+ medication trials
                        • Significant comorbidity (OCD, PTSD, bipolar)
                        • Substance use disorder
                        • Suicidal ideation
                        • Need for specialized therapy (EMDR, DBT)
                  2. Action

                    CBT Referral

                    Evidence-based psychotherapy

                    • Cognitive restructuring of anxious thoughts
                    • Exposure therapy for specific fears
                    • Relaxation training
                    • 8-12 weekly sessions typical
                    • Digital CBT programs available (Silvercloud, Woebot)
                  3. Action

                    Panic Disorder Specific

                    Additional considerations

                    • SSRI first-line (paroxetine, sertraline FDA-approved)
                    • CBT with interoceptive exposure
                    • PRN benzodiazepine for severe attacks only
                    • Educate about panic attack benign nature
                    • Rule out cardiac causes if atypical
            2. Warning

              Severe (15-21)

              Combination therapy or specialist referral

              • SSRI/SNRI + CBT recommended
              • Consider psychiatric referral
              • Short-term benzodiazepine only if severe/acute
              • Weekly follow-up initially
              • Assess for comorbid depression (common)

Guideline Source

GAD-7: A Brief Measure for Assessing Generalized Anxiety Disorder

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • GAD-7 is a screening tool, not diagnostic for specific anxiety disorders
  • Does not differentiate GAD from panic disorder, social anxiety, PTSD
  • Somatic symptoms may indicate underlying medical conditions
  • Does not assess substance-induced anxiety
  • May underestimate anxiety in stoic or somatizing patients

Contraindicated Populations

pediatric

Applicable Regions

USAUUKEU

AU: RACGP recommends validated tools like GAD-7 for anxiety screening

UK: NICE recommends GAD-7 for case identification in primary care

US: APA endorses GAD-7 for primary care screening

Version 1Next review: 2028-01-01

Frequently Asked Questions

What is the Anxiety Disorders Screening & Initial Management (GAD-7)?

The Anxiety Disorders Screening & Initial Management (GAD-7) is a diagnostic clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on GAD-7: A Brief Measure for Assessing Generalized Anxiety Disorder.

What guideline is the Anxiety Disorders Screening & Initial Management (GAD-7) based on?

This algorithm is based on GAD-7: A Brief Measure for Assessing Generalized Anxiety Disorder (DOI: 10.1001/archinte.166.10.1092).

What are the limitations of the Anxiety Disorders Screening & Initial Management (GAD-7)?

Known limitations include: GAD-7 is a screening tool, not diagnostic for specific anxiety disorders; Does not differentiate GAD from panic disorder, social anxiety, PTSD; Somatic symptoms may indicate underlying medical conditions; Does not assess substance-induced anxiety; May underestimate anxiety in stoic or somatizing patients. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Anxiety Disorders Screening & Initial Management (GAD-7) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free